Literature DB >> 25935198

Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use.

Jessica M Franklin1, Wesley Eddings, Sebastian Schneeweiss, Jeremy A Rassen.   

Abstract

INTRODUCTION: The Premier Perspective hospital billing database provides a promising data source for studies of inpatient medication use. However, in-hospital recording of confounders is limited, and incorporating linked healthcare claims data available for a subset of the cohort may improve confounding control. We investigated methods capable of adjusting for confounders measured in a subset, including complete case analysis, multiple imputation of missing data, and propensity score (PS) calibration.
METHODS: Methods were implemented in an example study of adults in Premier undergoing percutaneous coronary intervention (PCI) in 2004-2008 and exposed to either bivalirudin or heparin. In a subset of patients enrolled in UnitedHealth for at least 90 days before hospitalization, additional confounders were assessed from healthcare claims, including comorbidities, prior medication use, and service use intensity. Diagnostics for each method were evaluated, and methods were compared with respect to the estimates and confidence intervals of treatment effects on repeat PCI, bleeding, and in-hospital death.
RESULTS: Of 210,268 patients in the hospital-based cohort, 3240 (1.5 %) had linked healthcare claims. This subset was younger and healthier than the overall study population. The linked subset was too small for complete case evaluation of two of the three outcomes of interest. Multiple imputation and PS calibration did not meaningfully impact treatment effect estimates and associated confidence intervals.
CONCLUSIONS: Despite more than 98 % missingness on 24 variables, PS calibration and multiple imputation incorporated confounders from healthcare claims without major increases in estimate uncertainty. Additional research is needed to determine the relative bias of these methods.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25935198      PMCID: PMC4449313          DOI: 10.1007/s40264-015-0292-x

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  29 in total

1.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Authors:  S Schneeweiss; J D Seeger; M Maclure; P S Wang; J Avorn; R J Glynn
Journal:  Am J Epidemiol       Date:  2001-11-01       Impact factor: 4.897

2.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

Authors:  Adnan Kastrati; Franz-Josef Neumann; Stefanie Schulz; Steffen Massberg; Robert A Byrne; Miroslaw Ferenc; Karl-Ludwig Laugwitz; Jürgen Pache; Ilka Ott; Jörg Hausleiter; Melchior Seyfarth; Michael Gick; David Antoniucci; Albert Schömig; Peter B Berger; Julinda Mehilli
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

3.  Unpredictable bias when using the missing indicator method or complete case analysis for missing confounder values: an empirical example.

Authors:  Mirjam J Knol; Kristel J M Janssen; A Rogier T Donders; Antoine C G Egberts; E Rob Heerdink; Diederick E Grobbee; Karel G M Moons; Mirjam I Geerlings
Journal:  J Clin Epidemiol       Date:  2010-03-25       Impact factor: 6.437

4.  How many imputations are really needed? Some practical clarifications of multiple imputation theory.

Authors:  John W Graham; Allison E Olchowski; Tamika D Gilreath
Journal:  Prev Sci       Date:  2007-06-05

5.  Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention.

Authors:  Jeremy A Rassen; Murray A Mittleman; Robert J Glynn; M Alan Brookhart; Sebastian Schneeweiss
Journal:  Eur Heart J       Date:  2009-11-25       Impact factor: 29.983

6.  Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics.

Authors:  Sengwee Toh; Luis A García Rodríguez; Miguel A Hernán
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-05       Impact factor: 2.890

7.  Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.

Authors:  Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz-Josef Neumann; Katrin A Birkmeier; Sebastian Kufner; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati
Journal:  Eur Heart J       Date:  2010-02-11       Impact factor: 29.983

8.  Aprotinin during coronary-artery bypass grafting and risk of death.

Authors:  Sebastian Schneeweiss; John D Seeger; Joan Landon; Alexander M Walker
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

9.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

10.  Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery.

Authors:  Peter K Lindenauer; Penelope Pekow; Kaijun Wang; Benjamin Gutierrez; Evan M Benjamin
Journal:  JAMA       Date:  2004-05-05       Impact factor: 56.272

View more
  3 in total

1.  Propensity score analysis with partially observed covariates: How should multiple imputation be used?

Authors:  Clémence Leyrat; Shaun R Seaman; Ian R White; Ian Douglas; Liam Smeeth; Joseph Kim; Matthieu Resche-Rigon; James R Carpenter; Elizabeth J Williamson
Journal:  Stat Methods Med Res       Date:  2017-06-02       Impact factor: 3.021

2.  Health administrative data enrichment using cohort information: Comparative evaluation of methods by simulation and application to real data.

Authors:  Bernard C Silenou; Marta Avalos; Catherine Helmer; Claudine Berr; Antoine Pariente; Helene Jacqmin-Gadda
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

3.  Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.

Authors:  Sebastian Schneeweiss; Elisabetta Patorno
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 19.871

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.